Silence Other Operating Expenses from 2010 to 2024
| SLN Stock | USD 7.67 0.21 2.82% |
Other Operating Expenses | First Reported 2010-12-31 | Previous Quarter 75 M | Current Value 78.7 M | Quarterly Volatility 27.3 M |
Check Silence Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silence Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 274.8 K, Interest Expense of 32.3 K or Other Operating Expenses of 78.7 M, as well as many indicators such as Price To Sales Ratio of 18.97, Dividend Yield of 0.0 or PTB Ratio of 31.2. Silence financial statements analysis is a perfect complement when working with Silence Therapeutics Valuation or Volatility modules.
Silence | Other Operating Expenses |
Latest Silence Therapeutics' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Silence Therapeutics PLC over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Silence Therapeutics PLC. It is also known as Silence Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Silence Therapeutics' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Silence Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Silence Other Operating Expenses Regression Statistics
| Arithmetic Mean | 28,934,663 | |
| Geometric Mean | 17,040,503 | |
| Coefficient Of Variation | 94.41 | |
| Mean Deviation | 23,291,018 | |
| Median | 14,407,000 | |
| Standard Deviation | 27,318,421 | |
| Sample Variance | 746.3T | |
| Range | 77.8M | |
| R-Value | 0.92 | |
| Mean Square Error | 120.5T | |
| R-Squared | 0.85 | |
| Slope | 5,631,895 | |
| Total Sum of Squares | 10448.1T |
Silence Other Operating Expenses History
About Silence Therapeutics Financial Statements
Silence Therapeutics investors utilize fundamental indicators, such as Other Operating Expenses, to predict how Silence Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 75 M | 78.7 M |
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Silence Stock
| 0.8 | VTRS | Viatris | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.7 | ESPR | Esperion Therapeutics | PairCorr |
| 0.46 | BFRIW | Biofrontera Warrants | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Silence Therapeutics Correlation against competitors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.